2020-2027 Analysis and Review Fosfomycin Market

Fosfomycin Market

Fosfomycin Market By Clinical Application (Urinary Tract Infection and Prostatitis), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

14-05-2020 REP-HC-5085 40 Tables 120 pages Format

The fosfomycin market was valued at USD 434.5 Mn by 2019. Rising prevalence of urinary tract infection among the adult population worldwide primarily drives the fosfomycin market growth. The growing incidence of acute prostatitis in the geriatric population throughout the globe further accentuates the fosfomycin market growth.

Fosfomycin Market

Fosfomycin was developed in 1969 from the bacteria Streptomyces fradiae, but now it is developed synthetically by chemical reaction. It has a broad-spectrum activity against both the gram-positive and gram-negative bacteria especially against the E.coli and E. faecalis strain. It needs to be taken under medical supervision in order to prevent the occurrence of multidrug resistance and other side effects such as nausea, vomiting, vaginal yeast infections, etc.

The major segments related to the fosfomycin market are: 

By Clinical Application (2017–2027; US$ Mn)

Urinary Tract Infection

Prostatitis

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global fosfomycin market
  • The overall segmentation of the fosfomycin market, by clinical application, distribution channel, and geography is minutely studied. Urinary tract infection and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • Significant increase in the number of people suffering from urinary tract infection worldwide
  • Growing incidence of chronic prostatitis in men population throughout the globe further accentuate the fosfomycin market growth

Report gist?

  • The study of the global fosfomycin market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of fosfomycin owing to the rising prevalence of complicated urinary tract infection worldwide
  • The report will benefit researchers engaged in the development of fosfomycin drug formulation for its therapeutic efficacy in the treatment of chronic prostatitis
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to fosfomycin market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Urinary tract infection is presently spearheading the clinical application segment for fosfomycin market. Constant rise in urban industrialization in developing countries has resulted in a significant increase in water and soil pollution. Repeated exposure to causative agents such as E.coli and E. faecalis in slum areas further increases the occurrence of urinary tract infection. According to the World Health Organization (WHO), it is estimated that approximately 50% to 60% of the global women population is subjected to urinary tract infection during their lifetime. Prostatitis is estimated to register rampant market growth in the near future owing to the increasing geriatric population suffering from acute prostatitis due to urine leakage in the prostate gland. 

Hospital pharmacy is currently dominating the distribution channel segment for fosfomycin market. It is imperative to understand that noncompliance with drug posology can cause multidrug resistance to E. coli and E. Faecalis, hence precise compounding by hospital pharmacists in accordance with doctor’s prescription is mandatory. Retail pharmacy is anticipated to be the fastest-growing distribution channel during the forecast period on account of its ability to provide drugs at affordable cost price and increasing demand for generic medicines worldwide. 

North America is currently leading the geography segment for fosfomycin market. The rising prevalence of urinary tract infection in the adult population primarily drives the fosfomycin market growth in the region. According to the latest statistics provided by the National Institute of Health (NIH), approximately 25% of the women population in the United States are suffering from urinary tract infection per year. Additionally, the affordable reimbursement scenario for the fosfomycin drug formulations further bolster the market growth in the region. Europe is the 2nd largest regionals segment for the fosfomycin market. The rising prevalence of prostatitis in the male population in the East European region determines the fosfomycin market growth in the region. As per the latest research citings provided by the European Association of Urology the prevalence rate of chronic prostatitis in the male population ranges from 4.5% to 9% having a recurrent rate of 50% with the increasing age. Asia Pacific is set to be the fastest-growing regional segment for fosfomycin market. Increasing urbanization has led to water and soil pollution thereby increasing the exposure to E.coli and E. faecalis which causes the occurrence of complicated urinary tract infection. Furthermore, the establishment of a flourishing generic drug market further propels the fosfomycin market growth in the Asia Pacific region. 

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.